Clinuvel to evaluate SCENESSE as therapy in vitiligo
Filed with ASX ·
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Clinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- FDA provides positive guidance on Clinuvel`s EPP program
- EMA acknowledges Clinuvel filing afamelanotide in Europe `11
- Clinuvel records first A$1 million in sales
- Clinuvel presents SCENESSE to global porphyria conference
- Clinuvel granted Australian formulation patent
Later from Clinuvel Pharmaceuticals
- SCENESSE attains breakthrough European Market Authorisation
- SCENESSE Treatment in Europe
- SCENESSE launched in Europe
- FDA awards SCENESSE Fast Track designation for EPP treatment
- FDA accept SCENESSE clinical data package for NDA submission
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals